The Effectiveness of Aspirin on Preventing Pre-eclampsia

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study will explore the effectiveness of low-dose aspirin on preventing pre-eclampsia in high-risks pregnant women by comparing the incidence of pre-eclampsia and pregnancy outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The Third Affiliated Hospital of Guangzhou Medical University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Age between 18-55 years

• Gestational age between 12-20 weeks of pregnancy

• High risk of developing pre-eclampsia

• At least one of the following risk factors: Pre-eclampsia in a previous pregnancy , Multiple pregnancy，Diabetes Mellitus(Type 1 or 2), Chronic Hypertension，Renal disease, Autoimmune disease.

• At least two of the following risk factors: Primiparity，Pre-pregnancy Body Mass Index ≥28kg/m2, Age ≥35 years, Family members have a history of pre-eclampsia.

• Maternal informed conset obtained

Exclusion Criteria:

• Contraindication to aspirin therapy (including but not limited to allergy and high bleeding risk)

• Patient with known intention to terminate pregnancy

• Fetal abnormalities detected （including but not limited to major fetal malformation and FGR）

• Severe heart, liver, renal disease who can not burden the experiment

• Alcohol and drug abuse

• Being in another drug experiment within 3 months